Product logins

Find logins to all Clarivate products below.


Crohn’s Disease – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of Crohn’s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the total and diagnosed prevalence of Crohn’s disease for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s Crohn’s disease forecast answers the following questions:

  • Of all people with Crohn’s disease, how many in each country have been formally diagnosed?
  • Of all people diagnosed with Crohn’s disease, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Crohn’s disease over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following Crohn’s disease subpopulations:

  • Diagnosed prevalent cases.
  • Diagnosed incident cases.
  • Diagnosed prevalent cases by disease behaviour.
  • Diagnosed prevalent cases by disease location.
  • Diagnosed prevalent cases by disease severity.
  • Diagnosed prevalent cases by treatment scheme.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards;…
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…
Report
Malignant Melanoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy, and Opdualag (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combinations such as Roche /…
Report
Ulcerative Colitis – Landscape & Forecast – Disease Landscape & Forecast (G7)
We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s…